BOSTON--(BUSINESS WIRE)--Laurie H. Glimcher, MD, an internationally recognized immunologist, has been named the next president and CEO of the Dana-Farber Cancer Institute, the Board of Trustees announced today. Glimcher is currently the Stephen and Suzanne Weiss Dean of the Medical College at Weill Cornell Medicine in New York City, where she is also professor of medicine and provost for medical affairs at Cornell University.
"Dr. Glimcher is in many ways an ideal choice for Dana-Farber," said Josh Bekenstein, chairman of the Dana-Farber Board of Trustees. "She is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research. She has had extraordinary success as the leader of a major academic medical institution. Most importantly, she has a deep understanding of the latest developments in cancer research and care, and a clear vision of how Dana-Farber can most powerfully affect the fight against cancer."
Glimcher will begin at Dana-Farber in January, and current President Edward J. Benz, Jr., MD, has agreed to remain as president until her arrival at the Institute. She will also be a professor of medicine at the Harvard Medical School.
The Dana-Farber CEO plays an important role across the Harvard University-affiliated health sciences organizations, and Glimcher will serve as president of Dana-Farber/Partners Cancer Care, principal investigator of Dana-Farber/Harvard Cancer Center, and trustee of Dana-Farber/Boston Children's Hospital Cancer Care.
"It is an enormous honor and privilege to be chosen as the next leader of the Dana-Farber Cancer Institute," said Glimcher. "The opportunity to advance Dana-Farber's groundbreaking research and to improve the care available to patients with cancer is truly special to me, and I am thrilled to be returning home to Boston. Cancer research and care have reached a transformative moment in science, and I look forward to working with all of Dana-Farber's clinicians and scientists to find innovative therapies in the coming years."
Glimcher has strong ties to the Harvard medical community. Prior to joining Weill Cornell Medicine, Glimcher was the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School, where she headed one of the top immunology programs in the world. She is widely considered to be one of the world leaders in understanding cellular differentiation pathways in lymphocytes and has made seminal discoveries of key transcription factors that drive lineage commitment and activation in the immune system. Most recently she has discovered a critical signaling pathway in both tumor cells and in host immune responses, translating her basic discoveries in the control of immune cell differentiation into a new approach to cancer immunotherapy.
Glimcher received her postdoctoral training at Harvard and in the Laboratory of Immunology at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, and is board certified in Internal Medicine and Rheumatology. She received her BA degree from Radcliffe College and her MD from Harvard Medical School.
She has contributed more than 350 scholarly articles and papers to the medical literature. In addition, she is a fellow of the American Academy of Arts and Sciences, a member of the Institute of Medicine of the National Academy of Sciences and a member of the National Academy of Sciences. She is the former president of the American Association of Immunologists.
In addition, she has been honored by many organizations, including the Soma Weiss Award for Undergraduate Research, the Distinguished Young Investigator Award from the American College of Rheumatology, the Leukemia Society's Stohlman Memorial Scholar Award, the Arthritis Foundation's Lee S. Howley Award, the FASEB Excellence in Science Award, the American Society of Clinical Investigation Investigator Award, the Klemperer Award, the AAUW Senior Scholar Award, the Huang Meritorious Career Award, the AAI Excellence in Mentoring Award, the Dean's Award for Leadership in the Advancement of Women Faculty, the American College of Rheumatology Distinguished Investigator Award, the Ernest Bertner Award and the William Coley Award, among others. Most recently, Glimcher received the Indiana University School of Medicine Steven C. Beering Award for outstanding research contributions to advancement of biomedical or clinical science, and the L'Oréal-UNESCO Award for Women in Science.
She is a member of the American Asthma Foundation and Cancer Research Institute Scientific Advisory Boards and served on the Burroughs-Wellcome Fund and HHMI Scientific Advisory Boards. She sits on the Board of Trustees of Memorial Sloan Kettering Cancer Center and is on the Corporate Board of Directors of the Bristol-Myers Squibb Pharmaceutical Corporation and the Waters Corporation.
About Dana-Farber Cancer Institute
From achieving the first remissions in childhood cancer with chemotherapy in 1948, to developing the very latest new therapies, Dana-Farber Cancer Institute is one of the world's leading centers of cancer research and treatment. It is the only center ranked in the top four of U.S. News and World Report's Best Hospitals for both adult and pediatric cancer care.
Dana-Farber participates in a wide range of collaborative efforts to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber/Brigham and Women's Cancer Center provides the latest in cancer care for adults; Dana-Farber/Boston Children's Cancer and Blood Disorders Center for children. The Dana-Farber/Harvard Cancer Center unites the cancer research efforts of five Harvard academic medical centers and two graduate schools, while Dana-Farber Community Cancer Care provides high quality cancer treatment in communities outside Boston's Longwood Medical Area.
Dana-Farber is dedicated to a unique, 50/50 balance between cancer research and care, and much of the Institute's work is dedicated to translating the results of its discovery into new treatments for patients locally and around the world.